BioStack Raises $9.5 Million Seed to Sell Hospital Records as Medical-AI Training Data

BioStack, a Y Combinator Spring 2026 company, has raised a $9.5 million seed round to turn hospital records in the United States, India, Brazil and Argentina into datasets for medical research and for training healthcare AI. The company claims access to more than 100 million de-identified patient records, a figure the funding coverage repeats without independent checking.

Entrackr reported the round on October 26 and named Peak XV, Afore Capital, DCVC, Emerson Collective, SV Angel, Verdict Capital, Streamlined Ventures and Y Combinator as participants. It did not say which of them led. Indian Startup News names Peak XV, DCVC and Afore Capital as the leads, so the lead investor depends on which outlet you read. Valuation was not disclosed by either.

What is being sold

BioStack links clinical notes, lab results, imaging, medications, treatment histories and outcomes into longitudinal patient records, according to Indian Startup News. Entrackr lists the intended uses as medical research, drug development and AI training. The listed analytical uses are disease modelling, biomarker discovery, patient stratification and treatment-response analysis.

Claim	Figure	Source
De-identified patient records	More than 100 million	Company, via Entrackr
X-ray, MRI and CT scans	Several hundred thousand	Company, via Entrackr
Telehealth audio transcripts	Several million	Company, via Entrackr
Countries with hospital partners	4	Indian Startup News
Team size	11	Indian Startup News

Every row is the company's own claim. No hospital partner is named in either report.

The founders and the stage

Indian Startup News says the company was founded in 2025. Sanat Mishra is co-founder and chief executive, with cancer genomics research at Stanford, Yale, Carnegie Mellon and the Max Planck Institute behind him. Parth Patwa is co-founder and chief technology officer, a former generative AI scientist at AWS. The team is 11 people.

The round size is large for an 11-person company: $9.5 million is about $864,000 per employee. That is The Terminal's arithmetic, and it describes how early the company is rather than how it is run. Pushpak Kedia, a vice president at Peak XV, said healthcare AI's next frontier depends on "access to high-quality, longitudinal data."

The consent question the reports skip

The data is described as de-identified, and the company says its platform has provider-specific workflows and "data privacy protocols". Indian Startup News's report does not describe patient consent mechanisms or the regulatory steps taken in each country, and Entrackr's does not either.

One concrete use is in India, where the company says it is helping connect cancer patients with an investigational cancer vaccine programme. The biotech company and the vaccine are not named, so that claim cannot be checked.

The pattern is familiar from recent coverage of a Y Combinator agent-security launch, where compliance language on the company's pages and in its listing did not line up. Different sector, same reading rule: a claim about records or certification is a claim until a document backs it.

Where it sits among recent rounds

BioStack sells data, not a model. A closer cousin in the site's coverage is Warp Sciences' $215 million Series A, which sells lab work rather than records, at roughly 22 times the cheque size.

What would confirm it

The company says the money goes to US and international expansion, platform development and hiring for engineering and research. The observable test is whether a hospital system, a pharmaceutical buyer or a regulator puts its name to the data network, because until one does, 100 million records is a number from the seller.